News

Immune Checkpoint Inhibitors ‘High-Risk Yet Promising’ for Cancer Patients Who Undergo Organ Transplant

A meta-analysis led by a researcher at Roswell Park Comprehensive Cancer Center has identified key factors that could improve outcomes for cancer patients treated with immune checkpoint inhibitors (ICIs) before or after a solid-organ transplant.

News

Roswell Park Quick Talks: Breast Cancer and ADCs, Risk of Second HPV-Related Cancer, Cognitive Function and ICIs

Experts from Roswell Park Comprehensive Cancer Center will give remarks on racial and ethnic disparities in outcomes among people with metastatic breast cancer; risk patterns for second cancers associated with human papillomavirus (HPV); ...

News

ASCO 2025 Highlights: Menin Inhibitor for Acute Myeloid Leukemia; Organ Transplant and Checkpoint Inhibitors

Roswell Park presentations include findings from KOMET-001 in AML, new insights on risk of organ rejection after ICI.

News

Roswell Park is Hiring!

Working at Roswell Park will afford you incredible opportunities to work alongside some of the nation’s foremost clinicians and researchers to broaden your career experiences and be part of a team that eases the burden of cancer.

News

Clinical Trial Offers CAR T-Cell Therapy Targeting MUC16 for Recurrent/Refractory Ovarian Cancer

Roswell Park Comprehensive Cancer Center is one of only four sites in the U.S. and the only one in New York State offering a phase 1 clinical trial of an investigational cellular therapy strategy for the treatment of recurrent or refractory ...

News

Join Roswell Park Experts at ASCO

Nearly two dozen experts from Roswell Park Comprehensive Cancer Center will be attending this year’s American Society of Clinical Oncology conference in Chicago, May 30-June 3, and we’d like to invite you to meet them.